↓ Skip to main content

Glioma-associated endothelial cells are chemoresistant to temozolomide

Overview of attention for article published in Journal of Neuro-Oncology, October 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

patent
1 patent
facebook
2 Facebook pages
f1000
1 research highlight platform

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
18 Mendeley
citeulike
1 CiteULike
Title
Glioma-associated endothelial cells are chemoresistant to temozolomide
Published in
Journal of Neuro-Oncology, October 2009
DOI 10.1007/s11060-009-9891-7
Pubmed ID
Authors

Jenilyn J. Virrey, Encouse B. Golden, Walavan Sivakumar, Weijun Wang, Ligaya Pen, Axel H. Schönthal, Florence M. Hofman, Thomas C. Chen

Abstract

Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas. Although well tolerated, temozolomide still has limited clinical efficacy. Following drug treatment, patient prognosis still remains poor; tumor recurrence is almost universal. We hypothesized that this lack of effectiveness with temozolomide is because this drug does not target the glioma microenvironment, which is highly vascular in malignant gliomas. To test this hypothesis we analyzed the effects of temozolomide on the tumor vasculature in vitro and in vivo. We found that this drug did not affect the viability or proliferation rate of endothelial cells isolated from human glioma specimens, although temozolomide was highly cytotoxic to the glioma cell lines U87MG and U251. Furthermore, temozolomide did not inhibit the migration of these glioma-associated endothelial cells, a key mechanism responsible for tumor angiogenesis. In in vivo studies, using the intracranial glioma mouse model, temozolomide did not cause a pronounced effect on microvessel density. Our findings show that temozolomide has no apparent effect on the glioma vascular microenvironment. Thus combination therapy with anti-vascular agents may enhance temozolomide effectiveness as glioma therapeutic protocol.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 28%
Student > Bachelor 3 17%
Student > Postgraduate 2 11%
Other 2 11%
Student > Master 2 11%
Other 4 22%
Readers by discipline Count As %
Agricultural and Biological Sciences 9 50%
Medicine and Dentistry 5 28%
Biochemistry, Genetics and Molecular Biology 1 6%
Unspecified 1 6%
Neuroscience 1 6%
Other 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 August 2015.
All research outputs
#2,049,475
of 9,385,140 outputs
Outputs from Journal of Neuro-Oncology
#100
of 1,284 outputs
Outputs of similar age
#18,128
of 78,043 outputs
Outputs of similar age from Journal of Neuro-Oncology
#5
of 31 outputs
Altmetric has tracked 9,385,140 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,284 research outputs from this source. They receive a mean Attention Score of 2.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 78,043 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.